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Abstract
Background: Thrombopoietin (Thpo) and its receptor (Mpl), which regulate megakaryopoiesis, are expressed in the
central nervous system (CNS), where Thpo is thought to exert pro-apoptotic effects on newly generated neurons.
Mpl expression has been analysed in brain tissue on transcript level and in cultured primary rat neurons and
astrocytes on protein level. Herein, we analysed Mpl expression in the developing and adult murine CNS by
immunohistochemistry and investigated the brain of mice with homozygous Mpl deficiency (Mpl
-/-) by MRI.
Results: Mpl was not detectable at developmental stages E12 to E15 in any resident cells of the CNS. From E18
onwards, robust Mpl expression was found in various brain areas, including cerebral cortex, olfactory bulb,
thalamus, hypothalamus, medulla, pons, and the grey matter of spinal cord. However, major developmental
changes became obvious: In the subventricular zone of the cerebral cortex Mpl expression occurred only during
late gestation, while in the hippocampus Mpl expression was detectable for first time at stage P4. In the white
matter of the cerebellum Mpl expression was restricted to the perinatal period. In the adult cerebellum, Mpl
expression switched to Purkinje cell. The majority of other Mpl-positive cells were NeuN-positive neurons. None of
the cells could be double-labelled with astrocyte marker GFAP. Mpl
-/- mice showed no gross abnormalities of the
brain.
Conclusions: Our data locate Mpl expression to neurons at different subdivisions of the spinal cord,
rhombencephalon, midbrain and prosencephalon. Besides neuronal cells Mpl protein is also expressed in Purkinje
cells of the adult cerebellum.
Background
Thrombopoietin (Thpo) and its receptor (Mpl), which
primarily regulate megakaryopoiesis, are also expressed
in the central nervous system (CNS). Although a 39
amino-acid fragment of the N-terminal domain of Thpo
shares significant homology with erythropoietin (Epo),
which acts as neuroprotective substance [1], and with
various neurotrophins [2], current data show pro-apop-
totic effects of recombinant Thpo on newly generated
neuronal cells in models of brain hypoxia/ischemia [3].
Expression of Thpo transcripts and/or protein has
been described in the developing and adult brain,
including the cerebral cortex, hippocampus, brain stem,
and cerebellum [3-7]. Thpo mRNA and protein have
been detected in neurons, astrocytes and microglia
derived from the cerebral cortex and the hippocampi, as
well as in Purkinje cells and in granule cells of the cere-
bellum [3,6]. Thpo seems to be involved in the inflam-
matory response of the brain, because some patients
with meningitis demonstrated elevated Thpo levels in
the cerebrospinal fluid [8-10]. Thpo is most likely pro-
duced locally, since its high molecular weight (about 70-
80 kDa) makes its crossing over the intact blood-brain
barrier rather unlikely [11]. Under experimental condi-
tions of hypoxia, Thpo mRNA expression is down-regu-
lated [3,6,8].
Thpo is thought to mediate its effects by binding to its
receptor Mpl. However, data on the expression and reg-
ulation of Mpl in the CNS are very limited. So far,
expression of Mpl mRNA has been described in the
CNS of mice, rats and humans [3,4]. Region-specific * Correspondence: christof.dame@charite.de
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and hippocampus. In primary rat neurons and astro-
cytes, Mpl expression has been confirmed by RT-PCR
and immunostaining. Under hypoxia Mpl mRNA levels
increased in astrocytes, but decreased in hippocampal
neurons, suggesting a differential regulation under cer-
tain conditions [3]. Additionally, we recently showed
that Mpl is expressed on transcript and protein levels
in cultured brain-derived endothelial cells of adult
mice [12].
Neither malformation nor functional deficits of the
CNS have yet been reported in transgenic mice with
homozygous deletion of the Thpo (Thpo
-/-)o rMpl
(Mpl
-/-) gene [13-15]. However, cerebral and cerebellar
hypoplasia have been described in some patients with
congenital amegakaryocytic thrombocytopenia (CAMT)
[16,17], which is caused by mutations in the ligand-
binding domain of the MPL. In the thrombocytopenia
and absent radii (TAR) syndrome, for which a defect
in Mpl signalling has been shown [18], cerebellar dys-
genesis either with/without agenesis of the corpus cal-
losum and delayed myelinisation have been reported
[19-21].
Herein, we analysed the Mpl expression pattern in the
developing and adult murine CNS by immunohisto-
chemistry in order to highlight cells sensitive to Thpo
and to identify the time frame for the highest activity of
the Thpo/Mpl system.
Results
Specificity of the Mpl antibody
To test the different anti-Mpl antibodies for specificity
in the brain, we compared the recognition pattern
between wild-type and Mpl
-/- mice. A monoclonal anti-
body directed against the murine Mpl (clone AMM2;
Kirin Brewery) and a commercially available antibody
directed against human Mpl (anti-human TpoR, clone
167639, R&D Systems) both displayed specific labelling
of brain parenchymal cells of neonatal wild-type mice,
but not in Mpl
-/- pups (Figure 1A). Labelling of the
choroid plexus may be unspecific (Figure 1A) as often
the case in this structure. Of note, consecutive sections
were also stained without using the primary antibody.
Additionally, we confirmed the specificity of the anti-
human Mpl antibody by comparing in situ hybridization
and immunohistochemistry in the same section of the
neonatal wild-type or Mpl
-/- brain (Figure 1B). Of note,
various clones of this anti-human antibody differed in
the quality of staining, and the best results were
obtained using the 167639 clone. Because of the com-
mercial availability of this antibody, we used it for the
rest of the analyses. The combined testing has been
quoted as a golden standard for validation of antibodies
to be used in immunohistochemistry [22].
Expression pattern of Mpl in the developing brain
Our analysis revealed no specific Mpl labelling in any
resident cells of the CNS at developmental stages E12
and E15 (Figure 2A-C). Signals detected in the dorsal
medulla at E12 may be an artefact (Figure 2A), since
these structures were larger in size than normal neuro-
blasts at E12 and had ragged shape; they were also
detected on consecutive sections incubated with second-
ary antibody alone.
From E18 onwards Mpl protein expression was detect-
able in the prosencephalon, midbrain, and rhombence-
phalon as well as in the spinal cord (Table 1). In the
telencephalon, Mpl-positive cells were detected in the
cerebral cortex, in the subventricular zone of the IV
th
ventricle and in the inner layers of developing olfactory
bulb, but not in the hippocampus and basal ganglia.
Widespread Mpl expression was found in the dience-
phalon (thalamus and hypothalamus) and mesencepha-
lon (superior and inferior colliculus); other areas
included the pons (metencephalon), medulla (myelence-
phalon), and the grey matter of the cervical spinal cord
( F i g u r e2D - G ,T a b l e1 ) .T h e r ew a sn ol a b e l l i n gw i t h i n
the lateral recesses of the secondary rhombic lip that
generates the external granule layer of the cerebellum or
granular cells of the vestibulo-cochlear anlage (data not
shown).
Even considering that the staining intensity does not
necessarily represent the strongest protein expression, it
appeared that Mpl expression peaked in the early neo-
natal period. At birth the number of Mpl-positive cells
increased as observed through many sections of different
stages in parallel. In the telencephalon, the newly devel-
oping cortical subventricular zone contained numerous
Mpl-positive cells with tangentially oriented processes,
but the developing white matter was devoid of any
labelling (Figure 2H). In addition, the caudal cortex con-
tained a densely packed positive cell cluster (Figure 2I).
Other clusters of Mpl-positive cells were located in the
diencephalon (caudal thalamus; Figure 2J) and in the
mes- and metencephalon (pons and medulla; data not
shown). The cerebellar white matter became Mpl-posi-
tive, but the lateral recessus of the IV
th ventricle and
granule cell streams remained Mpl-negative (data not
shown). Furthermore, deep regions of the vestibulo-
cochlear nuclei also contained Mpl expressing cells
(Figure 2K).
At P4, the abundant labelling of the cortical ventricu-
lar zone disappeared, leaving behind a few Mpl-positive
cells in the interface between the developing white mat-
ter and the inner cortical plate (Figure 3A). The subven-
tricular zone surrounding the IV
th ventricle had also
become Mpl-negative. The expression of all other areas
remained almost identical compared to P0 (Figures 3B-
D, Table 1)
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Page 2 of 13Figure 1 Validation of the Mpl antibody. (A) Comparison of two antibodies recognizing Mpl on cryosections from developing Mpl
-/- and wild-
type mice one day after birth. Left panel: rat monoclonal anti-mouse Mpl (Kirin Brewery), right panel: murine monoclonal anti-human Mpl (R&D
Systems). Specific labelling was observed in the brain tissue from wild-type mice (left columns), but was absent in Mpl
-/- mice (right columns). (B)
Combined in situ hybridization (top row) and immunolabelling (bottom row) on the same sections show that in wild-type mice (left column) the
anti-human Mpl antibody (R&D Systems) recognizes the same cells which are labelled by the riboprobe directed against mouse Mpl mRNA.
Arrows indicate double-labelled cells. Specific labelling is absent in the corresponding region of the Mpl
-/- mouse (right column). cb -
cerebellum; chp - choroid plexus; cp - cortical plate; me - medulla; p - pons; svz - subventricular zone; IV - forth ventricle. Scale bars: 50 μm in all
panels.
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Page 3 of 13Figure 2 Detection of Mpl-positive cells in the embryonic central nervous system. Schematic drawings show the positions of the
micrographs. During early embryonic development both brain and spinal cord are devoid of Mpl labelling. Left column shows representative
examples at E12 (A) and E15 (B, C). The green labelling on the blood vessels is unspecific as it also labels negative control sections incubated
without the primary antibody. By embryonic day 18 (E18) numerous Mpl-positive cells appear in the inner cortical plate, subventricular zone of
the fourth ventricle and parenchymal regions of rhombencephalon (D-G). At P0 the number of Mpl positive cells reaches its peak, spreading
throughout many brain regions (I, J, K), including the subventricular zone of the lateral ventricles (H). Dorsal is up, anterior to the left. chp -
choroid plexus; cp - cortical plate; dcn - dorsal cochlear nucleus; h - hippocampus; svz - subventriclar zone; wm - white matter; IV - forth
ventricle. Scale bar 50 μm.
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Page 4 of 13Three days later, at P7, the number of the Mpl-posi-
tive cells further diminished. Interestingly, we observed
diffuse labelling in the alveus and in some cells within
the hippocampal formation scattered underneath pyra-
midal cells of CA1 (Figure 3E). Other positive areas
included the ventral medulla, pons, cerebellar white
matter and various regions of the midbrain. Similarly,
Mpl-expression is maintained in most areas of the dien-
cephalon, including thalamus and hypothalamus (Figures
3F-H, Table 1).
Finally, immunohistochemical analysis revealed Mpl-
expressing cells also in the adult CNS. Mpl expressing
regions in the telencephalon included the cerebral cortex,
the hippocampus and the mantle zone of the olfactory
bulb (data not shown). Large areas in diencephalon (pre-
optic area; Figure 3I), midbrain and medulla oblongata
also contained Mpl positive cells at different density
(Table 1). In contrast to the earlier stages, Mpl was detect-
able in Purkinje cells of the cerebellum, but not longer in
the white matter (Figure 3J). Mpl-expressing cells in the
brainstem were found in dorsal cochlear nucleus (Figure
3K) and in the grey matter of the spinal cord (Figure 3L).
Characterization of Mpl expressing cells
To characterize the cells, which express Mpl in the
brain, we performed double immunohistochemistry with
antibodies directed against Mpl as well as with estab-
lished markers for neurons and astrocytes. All brain
areas on parasagittal sections through the middle of the
b r a i nw e r ee x a m i n e df o rap o s s i b l eo v e r l a p .T h em a j o r -
ity of Mpl-positive cells in the developing brain co-
expressed the pan-neuronal marker NeuN with one
exception: Mpl-expressing cells in the cerebellar white
matter did not co-express NeuN (Figure 4A), indicating
their possible glial origin. Since the Mpl-positive cells
appeared in the brain during the generative period of
small granule cells, we also performed double labelling
of Mpl with the early granule cell marker NeuroD, but
found no overlap in any of the examined regions (see
Figure 4B for representative examples).
Moreover, we performed double labelling with the
Mpl antibody and the astrocyte marker GFAP to investi-
gate Mpl expression in astrocytes under physiological
conditions. However, none of the Mpl-positive cells co-
expressed GFAP. Figure 4C shows three representative
examples at the developmental stages P0 and P7, as well
as in adult mice. Thus, the Mpl-positive cell population
in the perinatal and early postnatal murine CNS is
mostly neuronal, but definitely heterogenic. For exam-
ple, Mpl-positive cells in the developing cerebellar white
matter had elongated cell bodies and projections parallel
to the cerebellar cortex. These cells were negative for
both NeuN and GFAP, ruling out the populations of
outside-projecting deep cerebellar neurons and astro-
cytes (Figure 4A). Almost all cells of the developing cer-
ebellar cortex, including granule neurons and small
inhibitory neurons were Mpl-negative during perinatal
and early postnatal development (Figure 3C and 3G;
Figure 4A and 4B). However, in the adult cerebellum,
Mpl expression was located in Purkinje cells (Figure 3J).
Table 1 Expression pattern of Mpl protein in the
developing and adult mouse brain
Subdivisions E18.5 P0 P4 P7 Adult
Spinal cord
Cervical Grey matter ++ +
+
++ +/- ++
White matter - - - - -
Rhombencephalon
Myelencephalon Roof plate, cochlear
complex
++
+
+- + +
Medulla, r2-r8 + +
+
+ +/- ++
Metencephalon Pons, r1 + +
+
++ + +
Cerebellar white matter - +
+
++ -
Cerebellar cortex +
external granule layer
-- - --
Purkinje cells of
cerebellum
-- - -+
Midbrain
Mesencephalon Prepontine hindbrain - + + + +
Tegmentum + +
+
-++ +
Inferior colliculus + +
+
+ +/- ++
Superior colliculus ++ +
+
+ +/- ++
Prosencephalon
Diencephalon Prethalamus ++ +
+
+ +/- +
Thalamus ++ +
+
++ + ++
Pretectum + +
+
++ +
Preoptic area ++ +
+
+- + +
Hypothalamus + +
+
++ +
Telencephalon Basal ganglia - + + +/- +
Hippocampal formation - - +/- ++ +
Cerebral cortex,
subventricular zone
-/+ +
+
-- -
Cerebral cortex + + + + +
Olfactory bulb + + - - +
The rough estimates of the staining intensity are presented in different brain
regions between E18.5, one day before birth, early postnatal stages as well as
in the adult brain.
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Page 5 of 13Figure 3 Mpl protein in the neonatal and adult central nervous system of mice. Each column combines a schematic drawing to show
positions of photographed areas and four sets of pictures. Panel A-D: postnatal stage day 4 (P4); Panel E-H: postnatal stage day 7 (P7); Panel I-L:
adult CNS. Dorsal is up, anterior to the left. alv - alveus; CA1sp - cornu ammonis 1 pyramidal layer; cp - cortical plate; hpf - hippocampal
formation; gcl - granule cell layer; h - hippocampus; ml - molecular layer; Pj - Purkinje cells; rt - rostral thalamus; svz - subventriclar zone; wm -
white matter; scale bar: 50 μm.
Ivanova et al. BMC Developmental Biology 2010, 10:77
http://www.biomedcentral.com/1471-213X/10/77
Page 6 of 13Figure 4 Characterization of Mpl-positive cells. (A) Co-localization of Mpl and the pan-neuronal marker NeuN. Almost all Mpl-positive cells
(green) are NeuN+ neurons (red) with the exception of cerebellar white matter. (B) Double-labelling of sections for Mpl and NeuroD, an early
marker of granule cells. Mpl (green) does not overlap with NeuroD (red) in the cerebellum or in the hippocampus. (C) Expression of Mpl and the
astrocyte marker GFAP in different brain regions at P0, P7 and in the adult brain. There is no overlap between Mpl (green) and GFAP (red). cp -
cortical plate; egl - external granule layer; gcl - granule cell layer; h - hippocampus; wm - white matter. Scale bars: 20 μm in A and B, 50 μmi nC .
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Page 7 of 13Developmental changes in Mpl and Thpo mRNA
expression throughout development
To further clarify the data on the developmental pattern
of Thpo/Mpl expression, we analysed expression of both
genes in the brain of wild-type mice (Additional file 1).
RT-PCR analysis indicated a developmental up-regula-
tion of Thpo mRNA. Mpl transcript levels appeared to be
higher at very early stages (E9.5 to E13.5) compared to
the perinatal period and adulthood. However, it needs to
be considered that the tissue specimens of early embryo-
nic mice (prior to e15.5) could not be efficiently perfused
through the heart for technical reasons. Thus, Mpl
mRNA levels might be false high, if mRNA from circulat-
ing hematopoietic Mpl expressing progenitors has been
amplified in PCR analysis. This has been experimentally
proven by comparing Mpl mRNA levels in perfused vs.
non-perfused specimens of the adult mouse brain (Addi-
tional File 1). Beyond E 13.5, however, Mpl mRNA levels
remained stable, which is concordant with the data
obtained by immunohistochemistry.
Mpl and Thpo mRNA expression in primary neurons,
astrocytes, microglia, and neuronal stem cells
Furthermore, we examined the expression of Mpl mRNA
in cultured primary brain cells, including neurons, astro-
cytes, and microglia prepared from the developing rat
brain, and in neuronal stem cells prepared from adult
mouse brain. Amplification of Mpl transcripts showed
t h ep r e s e n c eo fMpl expression not only in neurons, but
also in cultured astrocytes (Figure 5A). A faint band for
Mpl transcripts has been found in microglia, most likely
resulting from contamination of this culture with astro-
cytes, which is a normal issue in preparing these cultures.
In murine neuronal stem cells, Thpo mRNA was highly
expressed, while these cells did not express detectable
amounts of Mpl mRNA (Figure 5B).
Gross morphology of the Mpl
-/- brain
Investigating the intracranial morphology of Mpl
-/- mice
in vivo in neonatal (P7) as well as in adult stages, we did
not detect any structural abnormalities on the macro-
scopic level in comparison to wild-type littermates. All
animals presented with normal development and distri-
bution of the white and the grey matter, inconspicuous
gyrification, proper width of the inner and outer cere-
bral fluid interspaces, and normal anatomical morphol-
ogy of the cerebrum as well as the cerebellum, as
presented exemplarily in Figure 6.
Discussion
To further elucidate the role of the Thpo/Mpl system in
the brain, we analysed herein the expression pattern of the
Mpl protein in the murine brain by immunohistochemis-
try. It becomes evident that the Mpl is developmentally
regulated, since Mpl is not detectable on protein levels at
the very early stages (E12 and E15) of brain development
(Figure 2A-C). Mpl protein expression seems to peak
around birth (Figure 2D-K) , but is maintained in the
adult murine brain (Figure 3; Table 1). Previous data
obtained by conventional RT-PCR showed slightly higher
Mpl mRNA expression in the fetal rat brain compared to
adult rat hippocampus and cortex [3]. Considerably high
Figure 5 Expression of Mpl mRNA in various primary brain-
derived cells. A. Expression of Mpl mRNA as analysed by RT-PCR in
neurons, astrocytes and microglia isolated from E17 rat brain. B.
Expression of Thpo, Mpl and Actb mRNA in neuronal stem cells of
adult mice. C. Expression of Mpl transcripts in the brain, spleen and
liver of adult mice as controls.
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Page 8 of 13Mpl transcript levels may result in part from circulating
hematopoietic cells as shown in our analysis of non-per-
fused brain tissue specimens (Additional File 1). However,
our data also indicate a spatial and temporal expression
pattern of Mpl within various areas of the developing and
adult brain (Table 1). This may be important for future
dissection of the regulation and function of the Thpo/Mpl
system in the brain.
During late gestation, Mpl-positive cells are located in
the inner layer of the cortex, in the subventricular zone
of the IV
th ventricle (Figure 2E) and in the olfactory
bulb, but not in the hippocampal formation of the tele-
ncephalon. Furthermore, Mpl-positive cells are located
in various areas of the diencephalon (including thalamus
and hypothalamus), in the inferior and superior collicu-
lus of the mesencephalon, in the pons and medulla, and
in the grey, but not in the white matter of the spinal
cord (Figures 2F-G; Table 1). The lack of Mpl-positive
cells in the secondary rhombic lip, which generates the
external granule layer of the cerebellum, and in granule
cells of the vestibulo-cochlear anlage may indicate that
the Thpo/Mpl system is active in cells generated from
the residential ventricular zone of the IV
th ventricle
rather than from the secondary subventricular zone.
This hypothesis is supported by the observation that the
lateral recesses of the IV
th ventricle and granule cell
streams, invading into the external cerebellar granule
layer and between the cochlear nuclei, remain Mpl-
negative at later stages.
During the neonatal period and in adulthood of mice,
Mpl expression remains robust in the diencephalon,
mesencephalon, myelencephalon and the grey matter of
the spinal cord (Table 1). Notably, the strongest varia-
tions of Mpl expression occur in the telencephalon and
Figure 6 In vivo MRI investigation of parenchymal brain abnormalities in Mpl
-/- mice.F o u rMpl
-/- mice were analysed in vivo in two
developmental stages (neonatal (P7) and adult) using a standardised high resolution MRI protocol comprising triplanar T2- and T2*-weighted
MRI. The cortex as well as the periventricular area including the subventricular zone (SVZ) can be most adequately appreciated in axial slice
directions (panel A); the thalami and the hippocampi in coronal slice directions (panel B); the cerebellum and the medulla oblongata in sagittal
slice directions (panel C). The brain parenchyma of neither neonatal nor adult Mpl
-/- mice presented with any gross abnormalities concerning
morphology, volume or signal alterations compared to healthy wild type mice.
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Page 9 of 13in the metencephalon: In the telencephalon, Mpl-posi-
tive cells are initially located in the cortical subventricu-
lar zone and in the caudal cortex (Figures 2H, I), but
not in the developing white matter. Later, the abundant
labelling of cells in the cortical subventricular zone dis-
appears. Only a few Mpl-positive cells can be detected
in the interface between the white matter and inner cor-
tical plate at P4 (Figure 3A). However, from P4 onwards,
Mpl is expressed in the hippocampus. Mpl receptor is
n o te x p r e s s e dt h r o u g h o u tt h eh i p p o c a m p u s ,b u ti n
some multipolar cells in the stratum lacunosum/molecu-
lare. This may be interesting, since the Thpo/Mpl sys-
tem plays a role in selecting neurons by neurotrophins
during ongoing neurogenesis [3].
The second major developmental change in Mpl
expression affects the cerebellum. Here, we observe Mpl
expression in the cerebellar white matter only during
the perinatal period, but no longer in the adult (Figure
3C, G, J; Table 1). Furthermore, Mpl expression in Pur-
kinje cells is obviously silenced during development, but
active in the adult cerebellum (Figure 3J). Both observa-
tions are of particular interest, since some patients with
CAMT or TAR-syndrome, both resulting in impaired
Mpl function, exhibit structural and functional abnorm-
alities of the brain, affecting particularly the cerebellum
[16,19-21].
Double-labelling with various cell lineage markers sug-
gest that most Mpl expressing cells are neurons, con-
firmed by staining with the pan-neuronal marker NeuN
( F i g u r e4 A ) .T h i si sc o n s i s t e n tw i t hp r e v i o u sd a t ai n d i -
cating Mpl expression in primary rat hippocampal neu-
rons as well as human SH-SY5Y and rat PC12 cells,
which both exhibit a neuronal phenotype [3,8,23]. We
could not detect Mpl protein in astrocytes by GFAP,
although Mpl has been previously identified in isolated
cortical astrocytes by RT-PCR and immunohistochemis-
try [3]. Thus, we re-evaluated Mpl expression in isolated
rat astrocytes and could indeed confirm expression of
Mpl transcripts (Figure 5). Either the sensitivity of
immunohistochemistry is too low to detect Mpl expres-
sion in brain tissue specimens, or in vitro conditions
cause up-regulation of Mpl mRNA expression. The later
hypothesis appears to be more likely, since Mpl mRNA
expression in astrocytes is known to be induced by
hypoxia [3]. The hypoxic up-regulation of Mpl expres-
sion in astrocytes contrasts the down-regulation of the
Mpl in neuronal cells under the same conditions [3],
raising the question whether the Thpo/Mpl system exhi-
bits a different role in astrocytes vs. neurons.
Ehrenreich et al. identified a proapoptotic role of
Thpo that seems to be restricted predominately to
immature neuronal cells, suggesting a role for Thpo in
the selection of differentiated neurons [3]. In line with
this report, we detected Mpl mRNA expression in
primary cortical neurons, but not in neuronal stem cells
(Figure 5). Thus, the combined data support the current
model that Thpo exhibits its proapoptotic role in matur-
ating neurons, whereas neuronal stem or progenitor
cells are largely unaffected. Thereby, Thpo may indeed
help to select neurons that acquire target-derived neuro-
trophic support [3]. Notably, Mpl up-regulation coin-
cides with a period of very active neurogenesis and
establishment of connectivity.
Mpl expression peaks in some crucial brain areas at a
period, when normal neurogenesis prunes. This raises
the question whether it may render neonates more sus-
ceptible than adults to the pro-apopotic effect of Thpo.
Such a condition may be of particular significance in the
case of intracranial or intraventricular haemorrhage,
since it leads to a massive release of circulating Thpo
into the brain. Experiments in a mouse model of uni-
lateral stroke showed that recombinant Thpo exhibited
significantly higher damage scores and extent of apopto-
s i s[ 3 ] .T ot h eb e s to fo u rk n o w l e d g e ,f u r t h e rd a t ao n
the function of Thpo in any model of ischemic or trau-
matic brain injury are not available yet.
The biological relevance of the Thpo/Mpl system still
needs to be further proven. Due to the developmental
changes in Mpl expression in the SVZ of the telence-
phalon and in the cerebellum (downregulation in the
white matter; upregulation in Purkinje cells) as well as
structural and functional abnormalities in the brain of
some patients with impaired Mpl function (CAMT,
TAR syndrome) affecting particularly the cerebellum
[16,19-21], we expected structural abnormalities in the
brain of mutant mice with homozygous Mpl deficiency.
Surprisingly, MRI scans of Mpl
-/- mice did not show
gross abnormalities in areas which predominately
express the Mpl during brain development or in adult-
hood. However, ultrasound and/or MRI examinations
and assessment of neurodevelopment (for example Bay-
ley Scales of Infant Development) should be undertaken
in patients with CAMT or TAR syndrome to get further
insights into the role of Thpo and Mpl in the brain. We
did not observe a reduced life span of Mpl
-/- mice. Preli-
minary data on H&E sections do not indicate cytomor-
phological changes in the brain of the Mpl
-/- mice (not
shown).
Conclusions
In summary, our immunohistochemical analysis shows
specific expression pattern of Mpl in various regions of
the brain. Most strikingly, Mpl expression showed two
major developmental changes in the telencephalon
(affecting the subventricular zone and the hippocampus)
and the cerebellum (affecting the white matter and Pur-
kinje cells). Furthermore, we observed that Mpl protein
expression in the brain is largely restricted to neuronal
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Page 10 of 13cells and in the adult brain to Purkinje cells of the cere-
bellum. We could not detect Mpl expression in resting
astrocytes, pointing either to expression levels below the
detection limit of immunohistochemistry or to an
expression limited to certain in vitro conditions. The
lack of Mpl expression in neuronal stem cells and the
pattern of Mpl expression in the brain parenchyma sup-
port the concept that Thpo is critical for the selection
of neurons to undergo apoptosis during a crucial period
of neurogenesis. One should be aware of these findings
prior to clinical trials on the use of the second genera-
tion of thrombopoiesis-stimulating agents in neonates,
since these thrombopoietin mimetic peptides or non-
peptide molecules are very small in size and molecular
weight [24]. Thus, these promising drugs need to be
tested whether they cross the blood-brain-barrier in
neonates.
Methods
Animal experiments
Wild-type CD1 mice (Charles River Laboratories, Sulz-
feld) were mated, and noon on the day of discovery of
the vaginal plug was designated embryonic day 0 (E0).
Mpl expression was analysed on embryonic day 12
(E12), E15, E18, at birth (P0), on postnatal day P1, P4
and P7, as well as in adult mice. Embryos E12-15 were
fixed in ice-cold 4% PFA overnight. For better penetra-
tion of the fixative, more mature embryos and pups
were additionally perfused through the heart under
lethal intraperitoneal thiopental anaesthesia. At least 3
animals have been used for each time point. For double-
labelling experiments we have examined at least 5 ani-
mals per one pair of markers.
Transgenic mice with homozygous deletion of the Mpl
gene (kindly provided by Warren S. Alexander, Walter &
Eliza Hall Institute of medical Research, Melbourne, Aus-
tralia) were used to validate immunohistochemistry and
in situ hybridization [13]. The tissue was treated identical
to that of wild-type animals. Two animals of each geno-
type have been examined at three time points. Homozy-
gous Mpl deletion was confirmed by PCR analysis of
genomic DNA. For PCR analysis, we applied the follow-
ing primers directed against DNA fragments of the trans-
genic and the wild-type alleles (GenBank Accession
No. NM_001122949): a) 2l Oligo lvg17 5′-TCCAAGG-
TAAA GCACTGAAGTCCA-3′, b) 2l Oligo lvg15
5′-GTCTCCATGGAGGCTTAGGTGGGA-3′,a n dc )
1l Oligo lvg19 5′-GAAGAGCTTGGCGGCGAATG-
GGCT-3′ [13].
All animal procedures fully complied with institutional
and state guidelines and were approved by the Institu-
tional Review Board.
Immunohistochemistry
After overnight cryoprotection of the brain tissue in 20%
ice-cold sucrose, the specimens were frozen in OCT
(Cryo-M-Bed, Bright Instrument Co. Ltd., Huntingdon,
Cambridgeshire, UK) and sectioned at 14 μm. Whole
embryos or brains of older animals were cut in parasa-
gittal direction, making twelve series of sections. Two of
them containing all sections between the midline and
lateral edge of the large hemispheres per animal have
been subjected to immunohistochemistry with and with-
out primary antibody and examined under the fluores-
cent microscope. The sections were washed in PBS
containing 0.1% (v/v) Triton X-100 (Sigma), then
blocked in PBS containing 0.1% bovine serum albumin
Fraction V (Roth, Karlsruhe, Germany), 10% FBS, 0.1%
Triton X-100 and 0.05% sodium azide (Sigma). Sections
from adult brain have been additionally postfixed with
ice-cold 4% PFA/PBS for 10 min and washed three
times with PBS containing Triton prior to the permeabi-
lization/blocking step. For immunohistochemical analy-
sis the sections were incubated at 4°C with the following
primary antibodies diluted in blocking solution: mouse
anti-human MPL (clone 167639; IgG2a;R & DS y s t e m s
Minneapolis, MN; final concentration 2.5 μg/ml), rat
anti-mouse Mpl (clone AMM2, 1:200; Kirin Brewery,
Tokyo, Japan; final concentration 5 μg/ml), mouse anti-
mouse NeuN (A60, IgG1; Millipore, Billerica, MA; final
concentration 2 μg/ml), goat anti-mouse NeuroD (N-19;
Santa-Cruz Biotechnology, Santa Cruz, CA; final con-
centration 0.4 μg/ml) and rabbit anti-cow GFAP (6F2;
DAKO, Glostrup, Denmark; final concentration 5.8 μg/
ml). After 3 washes, tissue specimens were incubated
with the appropriate secondary antibody for 1 hour at
room temperature and counterstained with DAPI (2 μg/
ml; Roche, Basel, Switzerland). Cy-2 anti-mouse IgG,
Cy-3 anti-goat or anti-rabbit IgG (Jackson ImmunoRe-
search, West Growe, PA) served as secondary antibo-
dies. The two subclasses of IgGs were differentiated by
either Alexa 594 anti-mouse IgG2a or Alexa 488 anti-
mouse IgG1 (Invitrogen,) as secondary antibodies. After
detection of the Mpl, sections were thoroughly washed
3 times, fixed with 4% PFA for 5 min to crosslink the
signal and processed for the second antibody the same
way, including appropriate blocking.
Microscopic analysis was performed using an epifluor-
escence microscope (AxioPlan 2 Imaging System; Carl
Zeiss, Jena, Germany). Photographs were taken with a
digital camera (AxioCAM MRc) using AxioVision 4.2
software (Carl Zeiss). While photographing the same
region of the knockout animal and its wild-type litter-
mate the same exposure and post processing has been
used to allow faithful comparison. One may note that
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to deviations in DAPI intensity, but we refrained from
adjusting it in Figure 1A.
In situ hybridization
To validate the Mpl antibody, freshly-cut 14 μmc r y o -
sections from wild-type and Mpl
-/- mouse brain were
first subjected to in situ hybridization with an antisense
riboprobe against mouse Mpl followed by immunostain-
ing with the anti-human Mpl antibody. In situ hybridi-
zation was performed as described [25]. The detailed
protocol is available at http://www.ucl.ac.uk/~ucbzwdr/
richardson.htm. The digoxigenin-labeled riboprobe was
transcribed from a ~2kb cDNA encoding the full-length
murine Mpl cDNA (GenBank Accession No.
NM_001122949) cloned into pSPT18 vector (kindly pro-
vided by Michelle Souyri, Hôpital Paul Brousse Villejuif,
France) [26].
Preparation of primary cells from the brain
Primary neuronal cultures of cerebral cortex from Wis-
tar rat embryos (E17) were prepared as previously
described [27]. Astroglial and microglial cell cultures
were prepared from newborn rats as described else-
where [28]. Microglial cells were seeded at a density of
100,000 cells/cm
2 and harvested after 24 h. Astrocytes
were seeded at a density of 120,000 cells/cm
2 and har-
vested after 48 h. Adult neural stem cells (NSC) were
prepared from C57/Bl6 mice as described [29]. NSC
were cultivated in NBMA (Invitrogen) containing 2%
B27 without retinoic acid (Invitrogen), 1% L-glutamine,
10 ng/ml bFGF, and 20 ng/ml EGF (Biochrom, Berlin,
Germany).
RT-PCR analysis of Mpl expression
Mpl mRNA expression was analysed in primary brain-
derived cells by conventional RT-PCR analysis. Total
RNA was prepared using TRIzol reagent® (Invitrogen),
and first strand cDNA synthesis was performed with 2
μg of total RNA using oligo(dt) primers (Promega,) and
M-MLV reverse transcriptase (Invitrogen). One-twenti-
eth of reaction product was used for PCR amplification
in a thermal cycler, which was carried out under the
following conditions: DNA denaturation at 94°C for
60 seconds, primer annealing at 60°C (or 55°C rat Mpl)
for 60 seconds, extension of double-stranded DNA at
72°C for 90 seconds. The following primers were used:
mouse or rat Mpl 5′-CTAGCTCCCAAGGCTTCTTC-3′
(forward primer), 5′-GGCTCCAGCACCTTCCAGTCC
-3′ (reverse primer), product size 392 bp (GenBank
Accession No. NM_001122949); mouse Thpo
5′-CTCTGTCCAGCCCCGTAGC-3′ (forward primer),
5′-CCCCAA GAGGAGGCGAAC-3′ (reverse primer),
product size 314 bp (GenBank Accession No.
NM_009379); mouse Actb 5′-ACTGCTCTGGCTCC-
TAGCAC-3′ (forward primer), 5′-ACATCTGCTGGA
AGGTGGAC-3′ (reverse primer), product size 115 bp
(GenBank Accession No. NM_007393); rat Actb 5′-
ATCGTGGGCCGCCTAGCACC-3′ (forward primer),
5′-CTCTTTAATGTCACGCACGATTTC-3′ (reverse
primer), product size 542 bp (GenBank Accession No.
NM_031144). Amplified PCR fragments were visualized
on 1.5% agarose gel stained with ethidium bromide.
MRI analysis
Cerebral MRI was performed on a 7 Tesla rodent MRI
scanner (Pharmascan 70/16AS, Bruker BioSpin, Ettlin-
gen, Germany), applying a 20 mm RF-Quadrature-
Volume head coil. Animals received anesthesia via
facemask induced with 3% and maintained with 1.5 -
2.0% isoflurane (Forene, Abbot, Wiesbaden, Germany)
delivered in 100% O2 under constant ventilation control
(Bio Trig System, Bruker BioSpin, Ettlingen, Germany).
Mice were placed on a heated circulating water blanket
to keep up body temperature at 37°C. IRB protocol
G0240/06, Landesamt für Gesundheit und Soziales,
Berlin, Germany.
Triplanar fat-suppressed turbo spin echo T2-weighted
(RARE; TE1 14.5 ms, TE2 65.5 ms, TR 4500 ms, 0.5 mm
slice thickness, Matrix 256 × 256, FOV 2.8 cm, eight
averages, 40 coronal slices, scan time 28 minutes, and 20
axial slices, scan time 28 minutes) and T2*-weighted
(GEFI; TE 5.6 ms, TR 1200 ms, flip angle 35°, 0.5 mm
slice thickness, Matrix 256 × 256, FOV 2.8 cm, four
averages, 40 coronal slices, scan time 20 minutes, and 20
axial slices, scan time 13 minutes) images were acquired.
Identical slice positions were used for all sequences
applied: coronal slices were aligned to the olfactory bulb/
frontal lobe fissure and covered the entire brain up to the
cervical spinal cord. Axial slices were positioned parallel
to a plane through the most frontal tip of the olfactory
bulb and the most rostral cerebellar part. MRI data were
analysed using the MEDx3.4.3 software package (Medical
Numerics, Virginia, USA) on a LINUX workstation.
Additional material
Additional file 1: Analysis of expression of Thpo-mRNA and Mpl-
mRNA during the development of mouse brain. Conventional RT-PCR
analysis of Mpl and Thpo mRNA expression in the developing and adult
brain. Concerning relatively high Mpl transcript levels during early
embryonic development, one might take into account that the tissues
overlying the developing central nervous system contain circulatory
hematopoietic cells that carry Mpl. Transcardiac perfusion, often used to
minimize that, cannot be efficiently used before E15 for technical
reasons. This is supported by higher Mpl transcript levels in non-perfused
vs. perfused brain specimens.
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